Jens Kurreck

Sequence requirements in the catalytic core of the "10-23" DNA enzyme.

Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I.

Design of antisense oligonucleotides stabilized by locked nucleic acids.

Antisense technologies. Improvement through novel chemical modifications.

Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

RNA cleaving '10-23' DNAzymes with enhanced stability and activity.

Nucleic acids chemistry and biology.

Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1.

Expediting target identification and validation through RNAi.

Gaining target access for deoxyribozymes.

Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells.

Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.

Antisense and RNA interference approaches to target validation in pain research.

Deletion analysis in the catalytic region of the 10-23 DNA enzyme.

Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs.

Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.

Developing an effective RNA interference strategy against a plus-strand RNA virus: silencing of coxsackievirus B3 and its cognate coxsackievirus-adenovirus receptor.

Comparative crystallization and preliminary X-ray diffraction studies of locked nucleic acid and RNA stems of a tenascin C-binding aptamer.

Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.

RNA interference in pain research.

Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1.

siRNA efficiency: structure or sequence-that is the question.

Strand-specific silencing of a picornavirus by RNA interference: evidence for the superiority of plus-strand specific siRNAs.

Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice.

Inhibition of translation in living eukaryotic cells by an RNA G-quadruplex motif.

Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3.

Inhibition of picornaviruses by means of RNA interference.

ESF-EMBO symposium: antiviral applications of RNA interference.

RNA interference: from basic research to therapeutic applications.

Antiviral activity of highly potent siRNAs against echovirus 30 and its receptor.

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Locked nucleic acid aptamers.

Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.

RNA interference: Perspectives and caveats.

Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3.

Proof of RNA interference in humans after systemic delivery of siRNAs.

Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30.

Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions.

Design of small interfering RNAs for antiviral applications.

Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections.

Application of Mutated miR-206 Target Sites Enables Skeletal Muscle-specific Silencing of Transgene Expression of Cardiotropic AAV9 Vectors.

Adenovirus vector-mediated RNA interference for the inhibition of human parvovirus B19 replication.

A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DNA as a standard.

A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.

Identification and characterization of RNA guanine-quadruplex binding proteins.

Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir.

Targeting Highly Structured RNA by Cooperative Action of siRNAs and Helper Antisense Oligomers in Living Cells.

Use of a three-dimensional humanized liver model for the study of viral gene vectors.

Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.

Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients.

The Coxsackievirus and Adenovirus Receptor: Glycosylation and the Extracellular D2 Domain Are Not Required for Coxsackievirus B3 Infection.

Biological antivirals for treatment of adenovirus infections.